A multicentre validation study of the diagnostic value of plasma neurofilament lightNicholas J. Ashton, Oskar Hansson, Jan Lycke et al.|Nature Communications|2021Cited by 554
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Jan Lycke, Clas Malmeström et al.|Annals of Neurology|2010Cited by 347
Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosisMarkus Axelsson, Jan Lycke, Clas Malmeström et al.|Journal of Neurology|2010Cited by 192
Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long‐term outcome in patients with autoimmune encephalitisRadu Constantinescu, Henrik Zetterberg, David Krýsl et al.|European Journal of Neurology|2016Cited by 58
Cerebrospinal fluid neurofilament light and tau protein as mortality biomarkers in parkinsonismRadu Constantinescu, Markus Axelsson, Lars Rosengren et al.|Acta Neurologica Scandinavica|2019Cited by 24